MDxHealth S.A. (MDXH)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 18 | 22 | 37 | 70 | 90 | 108 | 82 | 111 |
| Operating profit | $m | -15 | -17 | ||||||
| Net profit | $m | -29 | -29 | -44 | -43 | -38 | -34 | -30 | -25 |
| EPS reported | $ | -0.67 | -0.59 | ||||||
| Operating cashflow per share | $ | -0.21 | -0.02 | ||||||
| Capex per share | $ | 0.02 | 0.01 | ||||||
| FCF per share | $ | -0.23 | -0.03 | ||||||
| Free cash flow | $m | -12 | -6 | ||||||
| Net debt | $m | 58 | 77 | ||||||
| Book value equity | $m | -12 | -30 | ||||||
| Book value per share | $ | -0.24 | -0.58 | ||||||
| Number of shares | m | 50.03 | 52.42 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -14.77 | -5.87 | ||||||
| P/S LTM | x | 1.66 | 2.18 | ||||||
| P/FCF LTM | x | -15.43 | -32.10 | ||||||
| EV/EBITDA LTM | x | -17.47 | -31.59 | ||||||
| EV/Sales LTM | x | 2.27 | 1.32 | ||||||
| Earnings Yield LTM | % | -18.77% | -64.68% | ||||||
| FCF Yield | % | -6.48% | -3.11% | ||||||
| Quality | |||||||||
| ROE | % | +277.15% | +402.97% | ||||||
| ROIC | % | -14.55% | -12.74% | ||||||
| Operating margin | % | -14.28% | -16.59% | ||||||
| Gross margin | % | +59.74% | +57.68% | ||||||
| FCF/Sales | % | -10.73% | -2.01% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +19.80% | -9.08% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.12 | -0.05 | ||||||
| Net Debt/EBITDA | x | -4.72 | -11.07 | ||||||
| EBIT/Net interest | x | -1.27 | -0.92 | ||||||
| Net debt/market cap | % | +48.49% | +2.09% | ||||||
| Net debt/Equity | x | -4.76 | -2.54 | ||||||
| Gross debt/equity | x | -7.86 | -3.48 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free